Systematic Reclassification of Variants of Uncertain Significance in a Clinical Nephrogenomics Program: Insights from the RAPIDS Collaboration
Clinical Kidney Journal · 02.11.2026
DOI: 10.1093/ckj/sfag397 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 02.11.2026. Verfasst von Tung Lin Lee und 38 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
A nationwide nephrologist-led genetic testing program for suspected monogenic glomerular disease and unexplained chronic kidney disease was implemented across four tertiary hospitals in Singapore. Initial testing yielded a genetic diagnosis in 11.5% probands, while 77 (18.4%) harboured variants of uncertain significance (VUS) that could explain their kidney disease (VUS-congruent). We evaluated a structured pipeline for reclassifying VUS-congruent to likely pathogenic or pathogenic (LP/P) to improve diagnostic yield and clinical utility.
Methods
Probands with VUS-congruent were reviewed at monthly multidisciplinary genomic board meetings. A stepwise framework incorporated genotype–phenotype correlations (Step 1), then re-appraisal of existing evidence (Step 2) through review of population databases, literature and in-silico prediction. For VUS with high suspicion of pathogenicity (VUS-High), resolution strategies were recommended (Step 3), including familial variant-specific testing, deeper phenotyping, and functional studies. Primary outcome was the proportion of VUS-congruent reclassified to LP/P; secondary outcomes were improvements in diagnostic yield and clinical utility.
Results
Among 418 probands tested over 28 months, 77 (18.4%) had VUS-congruent. Step 2 reclassified 26/77 VUS-congruent to LP/P, with another 22/77 VUS-congruent stratified as VUS-High. Among these 22 recommended for Step 3, completed strategies were functional studies (n=8), segregation analysis (n=1), deeper phenotyping (n=1), phase determination (n=1) and combination strategies (n=6). This enabled VUS-High reclassification to LP/P for 16 additional probands. Overall, 42/77 probands (54.5%) had VUS-congruent reclassified to LP/P, increasing diagnostic yield from 11.5% to 21.5%. Among these, 28 (66.7%) experienced clinically meaningful management changes.
Conclusion
A structured, multidisciplinary VUS resolution workflow enabled considerable VUS reclassification, nearly doubling the diagnostic yield.
Zitieren
APA
Lee, T. L., Zhang, Y., Lim, T. S. T., Koh, C. T., Chong, K. Y., Titin, C., Tan, H. Z., Mok, I., Kwek, J. L., Lim, C. C., Choo, J. C. J., Goh, J., Kam, S., Cham, B., Lim, J. Y., Tan, E. S., Leow, E. H., Ng, Y. H., Yap, J. Y. C., …, & Ng, K. H. (2026). Systematic Reclassification of Variants of Uncertain Significance in a Clinical Nephrogenomics Program: Insights from the RAPIDS Collaboration. Clinical Kidney Journal. https://doi.org/10.1093/ckj/sfag397
Vancouver
Lee TL, Zhang Y, Lim TST, Koh CT, Chong KY, Titin C, et al. Systematic Reclassification of Variants of Uncertain Significance in a Clinical Nephrogenomics Program: Insights from the RAPIDS Collaboration. Clinical Kidney Journal. 2026. doi:10.1093/ckj/sfag397
BibTeX
@article{Lee2026,
author = {Lee, Tung Lin and Zhang, Yaochun and Lim, Tina Si Ting and Koh, Chee Teck and Chong, Kay Yuan and Titin, Christina and Tan, Hui Zhuan and Mok, Irene and Kwek, Jia Liang and Lim, Cynthia Ciwei and Choo, Jason Chon Jun and Goh, Jeannette and Kam, Sylvia and Cham, Breana and Lim, Jiin Ying and Tan, Ee Shien and Leow, Esther Huimin and Ng, Yong Hong and Yap, Jia Ying Celeste and Chao, Sing Ming and Chong, Siew Le and Lim, Ru Sin and Goh, Su Mein and Lim, Regina Shaoying and Yeo, See Cheng and Wang, Ziyin and Lim, Chia Wei and Chan, Dana Leng Hui and Lu, David and Teo, Sharon and Lau, Perry Y W and Than, Mya and Ng, Jun Li and Chan, Gek Cher and Da, Yi and Teo, Boon Wee and Yap, Hui Kim and Chin, Hui-Lin and Ng, Kar Hui},
title = {Systematic Reclassification of Variants of Uncertain Significance in a Clinical Nephrogenomics Program: Insights from the RAPIDS Collaboration},
journal = {Clinical Kidney Journal},
year = {2026},
doi = {10.1093/ckj/sfag397}
}
EUVIMED